Welcome to Markets Desk, here's what's moving the conversation today.
October has a reputation on Wall Street that its data simply doesn't support. Historically, stocks have performed in line with other months, and analysts at MarketWatch argue that the persistent fear of an autumn crash is itself a tradeable anomaly — patient investors who hold through the seasonal noise have consistently come out ahead.
Shifting to biotech, Axsome Therapeutics is drawing serious attention from the analyst community, with consensus price targets pointing to roughly thirty-five percent upside over the next twelve months. Revenue growth has been accelerating, and the company's pipeline in central nervous system treatments gives institutional buyers a credible fundamental case, not just a momentum story.
And on the insider activity front, Robinhood's chief financial officer Shiv Verma sold eleven thousand four hundred seventy-two shares, netting approximately one point three million dollars. The transaction represented seventeen percent of his directly held equity stake, which is a meaningful reduction. Insider sales don't always signal concern, but a disposition of that proportion draws scrutiny, particularly as Robinhood continues navigating a competitive retail brokerage landscape.
That's the tape. Markets Desk, signing off the floor.
